Zlotta A - Search Results

1

Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns.

Lawrentschuk N, Daljeet N, Ma C, Hersey K, Zlotta A, Fleshner N. Lawrentschuk N, et al. Among authors: zlotta a. Int Urol Nephrol. 2011 Mar;43(1):31-7. doi: 10.1007/s11255-010-9772-1. Epub 2010 Jun 12. Int Urol Nephrol. 2011. PMID: 20544283

2

Repeat prostate biopsy: who, how and when?. a review.

Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Djavan B, et al. Eur Urol. 2002 Aug;42(2):93-103. doi: 10.1016/s0302-2838(02)00256-7. Eur Urol. 2002. PMID: 12160578 Review.

3

Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.

Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A, Marberger M. Djavan B, et al. Among authors: zlotta ar. Urology. 2002 Oct;60(4 Suppl 1):4-9. doi: 10.1016/s0090-4295(02)01896-4. Urology. 2002. PMID: 12384156

4

An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.

Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B. Zlotta AR, et al. J Urol. 2003 May;169(5):1724-8. doi: 10.1097/01.ju.0000062548.28015.f6. J Urol. 2003. PMID: 12686818

5

An artificial neural network to predict the outcome of repeat prostate biopsies.

Remzi M, Anagnostou T, Ravery V, Zlotta A, Stephan C, Marberger M, Djavan B. Remzi M, et al. Among authors: zlotta a. Urology. 2003 Sep;62(3):456-60. doi: 10.1016/s0090-4295(03)00409-6. Urology. 2003. PMID: 12946746 Clinical Trial.

6

Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.

Irani J, Salomon L, Soulié M, Zlotta A, de la Taille A, Doré B, Millet C. Irani J, et al. Among authors: zlotta a. Urology. 2005 Mar;65(3):533-7. doi: 10.1016/j.urology.2004.10.003. Urology. 2005. PMID: 15780371

7

Prostate cancer prevention: past, present, and future.

Fleshner N, Zlotta AR. Fleshner N, et al. Cancer. 2007 Nov 1;110(9):1889-99. doi: 10.1002/cncr.23009. Cancer. 2007. PMID: 17893870 Free article. Review.

8

Pharmacotherapy for prostate cancer: the role of hormonal treatment.

Shahani R, Fleshner NE, Zlotta AR. Shahani R, et al. Discov Med. 2007 Aug;7(39):118-24. Discov Med. 2007. PMID: 18093474 Free article.

9

Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.

Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N. Al-Ghamdi AM, et al. Among authors: zlotta ar. J Urol. 2008 Apr;179(4):1332-4. doi: 10.1016/j.juro.2007.11.067. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289588

10

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Among authors: zlotta ar. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters